Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novo Nordisk
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A clinical trial comparing long term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus 104týdenní klinická studie srovnávající dlouhodobou kontrolu glykémie při léčbě inzulínem degludek/liraglutid (IDegLira) a při léčbě inzulínem glargin u pacientů s diabetem 2. typu
To compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve subjects with type 2 diabetes mellitus (T2DM) inadequately controlled...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
An open label, dose escalation safety and tolerability trial of the combination of s.c. recombinant human IL-21 (rIL-21) and sunitinib (phase 1) followed by an open label stratified randomized 2-arm trial of rIL-21 plus sunitinib versus sunitinib alone (phase 2a) in subjects with stage IV renal cell carcinoma. Trial Phase: 1/2a
Phase 1: To assess the safety and tolerability of increasing doses of recombinant human Interleukin-21 (rIL-21), administered s.c. in a thrice weekly regimen, in combination with sunitinib 50 mg once ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Efficacy and safety of liraglutide in combination with metformin compared to metformin alone, in children and adolescents with type 2 diabetes
To confirm the superiority of liraglutide at the maximum tolerated dose (0.6 mg, 1.2 mg, 1.8 mg) in combination with metformin in controlling glycaemia versus metformin and liraglutide placebo in chil...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
sa Novo Nordisk Pharma nv
MAJ Il y a 4 ans
A four-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once or twice daily in a basal-bolus regimen with insulin aspart in subjects with type 1 diabetes, followed by a three-month extension period
The primary objective of this trial is to compare the glycaemic control of once daily insulin detemir regimen with that of twice-daily insulin detemir regimen as measured by HbA1c in subjects with typ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A trial to compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily Norditropin® FlexPro® in adults with growth hormone deficiency
To demonstrate the efficacy of once weekly dosing of NNC0195-0092 compared to placebo after 34 weeks of treatment in adults with growth hormone deficiency
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk Farma Oy
MAJ Il y a 4 ans
A one-year, multi-national, open-labelled, parallel-group, 2:1 randomised treat-to-target trial comparing efficacy and safety of insulin detemir with insulin glargine using a basal-bolus regimen with insulin aspart as mealtime insulin in subjects with type 2 diabetes
To compare the glycaemic control of insulin detemir with that of insulin glargine as measured by HbA1c in subjects with type 2 diabetes on a basal-bolus regimen with insulin aspart as bolus insulin af...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Pharmacogenetic testing of saliva samples from patients in the adept™2 trial (NN1731-3562)
To determine the HLA type and polymorphisms in the FVII gene in patients previously exposed to rFVIIa analogue in the adept™2 trial
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A 20 weeks randomised, multinational, open labelled,2 parallel group comparison of biphasic insulin aspart (BIAsp) 30 in combination with metformin in subjects with type 2 diabetes, which is inadequately controlled on basal insulin analogues. One treatment group use twice daily titration of biphasic insulin aspart 30 driven by the subject, the other group use twice daily titration of biphasic insulin aspart 30 driven by the investigator. Both groups combine their treatment with metformin
To confirm efficacy of subject-driven titration of biphasic insulin aspart (BIAsp) 30 twice daily in terms of glycaemic control assessed by change in glucosylated haemoglobin (HbA1c). This is done b...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A single arm, single-centre, open-label, exploratory trial of recombinant Interleukin-21 administered subcutaneously for 4 weeks as neo-adjuvant treatment prior to sentinel lymph node/complete lymph node dissection followed by 8 weeks of adjuvant treatment in subject with stage III malignant melanoma
To estimate the complete response rate of the sentinel lymph node(s) as assessed by histopathology in subjects with stage III malignant melanoma measured after 4 weeks of local neo-adjuvant treatment ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis
To compare the effect of semaglutide subcutaneous (s.c.) once daily versus placebo on histological resolution of non-alcoholic steatohepatitis (NASH).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
11
12
13
14
15
16
17
18
19
20
Suivant